REG - Aptamer Group PLC - Patent submission for Optimer® binders

AptamerAnnouncement

08/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240408:nRSH6489Ja&default-theme=true

RNS Number : 6489J  Aptamer Group PLC  08 April 2024

     08 April 2024

 

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Patent submission for Optimer(®) binders in cosmetic products

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders to
enable innovation in the life sciences industry, today announces that it has
filed a patent application to protect the recently developed Optimer binder
sequences for novel applications in fast moving consumer goods generated as
part of its partnership with Unilever.

 

The patent was submitted on 28 March 2024. Submission of this patent
application reinforces the ongoing commercial protection of Aptamer Group's
leading technology position in the development of high-performance binders.

 

Aptamer Group developed the binders as part of a fee-for-service project and
has continued to support Unilever in validating the functionality of the
binders both in-house at Aptamer Group and within Unilever's own labs.
Submission of the patent at this stage establishes a 'priority date' for the
binder sequences, giving Aptamer Group precedence for the protection of the
intellectual property while allowing commercial negotiations to continue.

 

Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: "The
submission of this patent is an important milestone for Aptamer Group and
supports the next stages of commercial advancement with Unilever. We are
really pleased with the work performed by our scientists and those at Unilever
over the past few months to demonstrate the use of these Optimer binders and
their suitability for application in fast moving consumer goods. We will
continue to work closely with the team at Unilever to support their use of the
binders in this exciting new application."

Dr Samantha Samaras, Senior Vice President of R&D at Unilever, said: "Over
the past 12 months we have been working with the excellent team at Aptamer
Group to discover, develop and exploit their Optimer binders for cosmetic
applications. We look forward to continued collaboration in this exciting
applications space."

 

- ENDS -

 

For further information, please contact:

 

 

 Aptamer Group plc                                            +44 (0) 1904 217 404

 Steve Hull
 SPARK Advisory Partners Limited - Nominated Adviser          +44 (0) 20 3368 3550

 Andrew Emmott / Adam Dawes
 Turner Pope Investments (TPI) Limited - Broker               +44 (0) 20 3657 0050

 James Pope / Andrew Thacker

 

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary
Optimer(®) platform to enable new approaches in therapeutics, diagnostics,
and research applications. The Company strives to deliver transformational
solutions that meet the needs of life science researchers and developers.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global affinity ligand market is currently worth
over $170 billion.

Aptamer has successfully delivered projects for a range of global pharma
companies, diagnostic development companies, and research institutes, covering
multiple application areas with the objective of establishing royalty-bearing
licenses.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGUGDSBSGDGSI